Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


10-year old Spiriva helps asthmatics blow out the candles

This article was originally published in Scrip

Executive Summary

COPD therapy Spiriva, now with a decade of use behind it, may also have a role in treating uncontrolled asthma, according to data presented by Boehringer Ingelheim at the 2012 annual meeting of the European Respiratory Society in Vienna, Austria.

You may also be interested in...

Boehringer Ingelheim: Olodaterol set for US approval

The FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 15-1 in favor of approval of olodaterol 5µg as a once-daily maintenance bronchodilator for chronic obstructive pulmonary disease (COPD) (see story: FDA reviewers: Bronchodilation somewhat modest for BI’s olodaterol in COPD).

Generic Singulair threat becomes reality

As anticipated, Merck is about to face a significant decrease in revenue as the first generic versions of its blockbuster Singulair reach the US market as the FDA has approved the first generic versions of Merck's allergy and asthma drug. Although Merck's strong pipeline is aimed at offsetting the impact of generic erosion, little can be done in the immediate future to stem this loss.

Novartis combi approach will strengthen COPD drug franchise

While Novartis has attracted US and Japanese approvals for its COPD treatment indacaterol (inhalation powder), which will be marketed as Arcapta Neohaler and Onbrez Inhalation, respectively, it is the compound's potential in combination therapies that will underpin any blockbuster opportunity (, 4 July, 2011 and 4 July, 2011). Indacaterol's new approvals follow its EU authorisation as Onbrez Breezhaler in December 2009 (, 8 December 2009).


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts